Targeted Therapy
Progression-free survival was 15 months longer when Ibrance was added to standard treatment.
Enhertu is likely a valuable new treatment option for certain brain metastases.
Enhertu seems better than chemotherapy for metastatic breast cancers with even the lowest detectable levels of HER2.
More than eight years of follow-up from the KATHERINE trial showed the continued survival benefits of Kadcyla over Herceptin for HER2-positive breast cancer with a high risk of recurrence.
If approved, the medicine may be an alternative to Piqray for treating certain cancers with a PIK3CA mutation.
Adding Tukysa to Kadcyla improved outcomes for metastatic HER2-positive disease.
Truqap is a new targeted therapy option for metastatic, hormone receptor-positive breast cancer with specific genetic mutations that has stopped responding to other hormonal therapy medicines.
The experimental medicine Dato-DXd may be a new treatment option for certain metastatic, hormone receptor-positive breast cancers.
Five years of follow-up show Verzenio continues to reduce early-stage breast cancer recurrence risk long after people stop taking it.
Adding Kisqali to hormonal therapy after surgery reduces recurrence risk.
Chemotherapy — instead of hormonal therapy — plus two anti-HER2 medicines before surgery offered better pCR rates.
Tukysa plus the standard of care improved survival in people diagnosed with metastatic, HER2-positive breast cancer that had spread to the brain.
Trodelvy is now approved to treat metastatic, hormone receptor-positive breast cancer, rather than only triple-negative disease.
Pre-menopausal women diagnosed with advanced-stage, hormone receptor-positive, HER2-negative breast cancer got more benefits from Kisqali and hormonal therapy than chemotherapy as a first treatment.
The benefits of Verzenio after surgery for early-stage, hormone receptor-positive, HER2-negative breast cancer with a high risk of recurrence were confirmed with longer follow-up.
Updated results from the DESTINY-Breast02 and DESTINY-Breast03 studies confirmed the benefits of Enhertu for previously treated metastatic, HER2-positive breast cancer, and results from the TALENT trial suggest that the medicine may offer benefits for early-stage hormone receptor-positive, HER2-low breast cancer when given before surgery.
The latest results from the MONARCH 3 study show that adding Verzenio to an aromatase inhibitor improves overall survival by 12.6 months for advanced-stage, hormone receptor-positive, HER2-negative breast cancer.
When given as a first treatment, the combination of dalpiciclib — a new CDK4/6 inhibitor — with either Arimidex or Femara improved progression-free survival in women diagnosed with advanced-stage, hormone receptor-positive, HER2-negative breast cancer.
The targeted therapy Trodelvy improved overall survival by 3.2 months in people diagnosed with metastatic, hormone receptor-positive, HER2-negative breast cancer that was previously treated with hormonal therapy, a CDK4/6 inhibitor, and at least two lines of chemotherapy.
Patient-reported outcomes from the DESTINY-Breast04 study, which looked at using the targeted therapy Enhertu to treat metastatic HER2-low breast cancer, suggest Enhertu controls pain better than doctors’ choice of chemotherapy.
Colitis has been identified as a new side effect of the targeted therapy Piqray.
On Aug. 5, 2022, the U.S. Food and Drug Administration approved Enhertu to treat unresectable or metastatic HER2-low breast cancer.
Exercise helped reduce the risk of heart problems in women receiving treatment for breast cancer.
Trodelvy (chemical name: sacituzumab govitecan-hziy) slightly improved progression-free survival in people diagnosed with metastatic hormone receptor-positive, HER2-negative breast cancer previously treated with hormonal therapy, a CDK4/6 inhibitor, and multiple lines of chemotherapy.